Compare DSY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DSY | MURA |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | DSY | MURA |
|---|---|---|
| Price | $0.35 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 124.0K | ★ 224.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,323,356.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.97 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $0.32 | $0.95 |
| 52 Week High | $7.33 | $4.74 |
| Indicator | DSY | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 19.08 | 40.39 |
| Support Level | $0.32 | $2.06 |
| Resistance Level | $0.43 | $2.10 |
| Average True Range (ATR) | 0.02 | 0.01 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.87 | 25.00 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.